Patents by Inventor Douglas Anthony Kerr

Douglas Anthony Kerr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240026374
    Abstract: Described herein are ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette comprises a codon optimized nucleic acid sequence encoding a PAH protein, in combination with particular promoter sequences and cis-regulatory elements. Further provided herein are methods and cell lines for reliable gene expression of PAH protein in vitro, ex vivo and in vivo using the ceDNA vectors. Also provided herein are methods and compositions comprising ceDNA vectors useful for the expression of PAH protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing PAH protein. Such PAH protein can be expressed for treating disease, e.g., Phenylketonuria (PKU).
    Type: Application
    Filed: September 16, 2021
    Publication date: January 25, 2024
    Inventors: Leah Yu Liu, Russell Monds, Matthew James Chiocco, Nathaniel Silver, Phillip Samayoa, Douglas Anthony Kerr, Jessica Lynn Keenan
  • Publication number: 20230383311
    Abstract: The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding FVIII protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of FVIII protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are methods and compositions comprising ceDNA vectors useful for the expression of FVIII protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing FVIII protein. Such FVIII protein can be expressed for treating disease, e.g., hemophilia A.
    Type: Application
    Filed: September 16, 2021
    Publication date: November 30, 2023
    Inventors: Debra Klatte, Russell Monds, Luke S. Hamm, Nathaniel Silver, Phillip Samayoa, Douglas Anthony Kerr, Jessica Lynn Keenan
  • Publication number: 20230134550
    Abstract: The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding GBA protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of GBA protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of GBA protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing GBA protein. Such GBA protein can be expressed for treating disease, e.g., Gaucher disease.
    Type: Application
    Filed: March 24, 2021
    Publication date: May 4, 2023
    Inventors: Douglas Anthony Kerr, Phillip Samayoa, Nathaniel Silver, Luke S. Hamm
  • Publication number: 20230138409
    Abstract: The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding FIX protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of FIX protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of FIX protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing FIX protein. Such FIX protein can be expressed for treating disease, e.g., hemophilia B.
    Type: Application
    Filed: March 24, 2021
    Publication date: May 4, 2023
    Inventors: Douglas Anthony Kerr, Phillip Samayoa, Nathaniel Silver, Sebastian Aguirre, Debra Klatte, Eli Hertzel Pasackow
  • Publication number: 20230024354
    Abstract: The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding PAH protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of PAH protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of PAH protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing PAH protein. Such PAH protein can be expressed for treating disease, e.g., Phenylketonuria (PKU).
    Type: Application
    Filed: March 13, 2020
    Publication date: January 26, 2023
    Inventors: Douglas Anthony Kerr, Phillip Samayoa, Nathaniel Silver, Matthew Chiocco
  • Publication number: 20220228171
    Abstract: The present application discloses methods for synthetic production and cell-free synthesis of DNA vectors, particularly closed-ended linear DNA vectors having one or more gaps (e.g., nicked ceDNA vectors, “neDNA”) and adenoassociated-virus (AAV) vector which is single strand DNA having linear and continuous structure, for delivery and expression of a transgene in the host cell. The present invention also relates to an in vitro process for production of closed-ended DNA vectors, corresponding DNA vector products produced by the methods and uses thereof, and oligonucleotides and kits useful in the process of the present invention.
    Type: Application
    Filed: July 17, 2020
    Publication date: July 21, 2022
    Inventors: Ozan Alkan, Robert Michael Kotin, Douglas Anthony Kerr, Russell Monds, Carolyn Pelletier, Matthew Stanton
  • Publication number: 20220220488
    Abstract: The present application discloses methods for synthetic production and cell-free synthesis of single stranded adeno-associated virus (AAV) vectors, for delivery and expression of a transgene in host cells. The present invention also relates to an in vitro process for production of closed-ended DNA vectors and corresponding single stranded AAV DNA vector products synthesized from the closed-ended DNA vectors having nicks.
    Type: Application
    Filed: July 17, 2020
    Publication date: July 14, 2022
    Applicant: Generation Bio Co.
    Inventors: Ozan Alkan, Robert Michael Kotin, Douglas Anthony Kerr, Russell Monds, Carolyn Pelletier, Matthew Stanton
  • Publication number: 20220177545
    Abstract: The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding FVIII protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of FVIII protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of FVIII protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing FVIII protein. Such FVIII protein can be expressed for treating disease, e.g., hemophilia A.
    Type: Application
    Filed: March 13, 2020
    Publication date: June 9, 2022
    Inventors: Douglas Anthony Kerr, Debra Klatte, Phillip Samayoa, Nathaniel Silver
  • Publication number: 20220119840
    Abstract: Provided herein are methods and constructs related to minimizing immune responses using inhibitors of the immune response, in particular the innate immune response, when administering a desired transgene in a cell achieved by delivery of the transgene with repeated doses of a ceDNA vector.
    Type: Application
    Filed: January 24, 2020
    Publication date: April 21, 2022
    Inventors: Douglas Anthony Kerr, Phillip Samayoa, Robert M. Kotin, Matthew G. Stanton, Ozan Alkan, Matthew Chiocco, Raj Rajendran
  • Publication number: 20220042035
    Abstract: The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of an antibody or fusion protein in a cell, tissue or subject. Such antibodies or fusion proteins can be expressed for treating disease or alternatively, for the production of antibodies or fusion proteins in a commercial setting.
    Type: Application
    Filed: February 14, 2019
    Publication date: February 10, 2022
    Inventors: Ozan ALKAN, Douglas Anthony KERR, Robert Michael KOTIN, Debra KLATTE, Leah LIU, Nathaniel SILVER
  • Publication number: 20210071197
    Abstract: The application describes methods for synthetic synthesis and cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The present invention relates to an in vitro process for production of closed-ended DNA vectors, corresponding DNA vector products produced by the methods and uses thereof, and oligonucleotides and kits useful in the process of the invention. DNA vectors produced using the methods described herein are free from unwanted side effects due to contaminants introduced during production in cell lines, for example, bacterial or insect cell lines. Further provided herein are methods and cell lines for reliable gene expression in vitro, ex vivo and in vivo using the ceDNA vectors synthesized using the methods herein.
    Type: Application
    Filed: January 18, 2019
    Publication date: March 11, 2021
    Inventors: Ozan Alkan, Robert Michael Kotin, Matthew Stanton, Douglas Anthony Kerr, Carolyn Pelletier
  • Publication number: 20210059953
    Abstract: Provided herein are lipid nanoparticle formulations that comprise an ionizable lipid and non-viral, capsid-free DNA vectors with covalently-closed ends.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 4, 2021
    Inventors: Robert Michael Kotin, Ozan Alkan, Douglas Anthony Kerr, Ara Karl Malakian, Matthew John Simmons, Matthew G. Stanton, Jie Su, Teresa L. Wright
  • Publication number: 20200283794
    Abstract: CeDNA vectors having linear and continuous structure can be produced in high yields and used for effective transfer and expression of a transgene. ceDNA vectors comprise an expression cassette and two different ITR sequences derived from AAV genomes in a specified order. Some ceDNA vectors provided herein further comprise cis-regulatory elements and provide high gene expression efficiencies. Further provided herein are methods and cell lines for reliable and efficient production of the linear, continuous and capsid-free DNA vectors.
    Type: Application
    Filed: September 7, 2018
    Publication date: September 10, 2020
    Inventors: Robert Michael Kotin, Ozan Alkan, Annaliese Jones, Douglas Anthony Kerr, Ara Karl Malakian, Matthew John Simmons, Teresa L. Wright